MarcyEdmond490 at 09:02, 18 February 2026

2026-02-18T09:02:06Z

New page

{{Short description|Indian multinational pharmaceutical company}}
{{Use dmy dates|date=January 2016}}
{{other uses|CIPLA (disambiguation)}}
{{Infobox company
| name = Cipla Limited
| logo = Cipla logo.svg
| logo_size = 250px
| trading_name = Cipla
| former_name = Chemical Industrial & Pharmaceutical Laboratories Ltd. (1935–1984)
| type = [[Public company|Public]]
| traded_as = {{BSE|500087}}<br />{{NSE|CIPLA}}<br />[[NIFTY 50|NSE NIFTY 50]] constituent
| founder = [[Khwaja Abdul Hamied]]
| area_served = Worldwide
| key_people = {{Unbulleted_list|[[Yusuf Hamied|Y. K. Hamied]] {{small|([[Chairperson]])}}|Umang Vohra {{small|([[Chief executive officer|CEO]])}}}}
| ISIN = {{ISIN|sl=n|pl=y|INE059A01026}}
| industry = [[Pharmaceuticals]]
| products = {{hlist|[[Medication|Pharmaceutical drugs]]| [[generic drug]]s| [[antiviral drug]]s| [[over-the-counter drug]]s| [[vaccine]]s| [[Medical diagnosis|diagnostics]]| [[contact lens]]es| [[Veterinary medicine|animal health]]| [[dietary supplements]]|[[protein supplement]]s }}
| revenue = {{Increase}} {{INRConvert|27548|c}} (2025)
| operating_income = {{Increase}} {{INRConvert|7128|c}} (2025)
| net_income = {{Increase}} {{INRConvert|5273|c}} (2025)
| assets = {{Increase}} {{INRConvert|37387|c}} (2025)
| equity = {{Increase}} {{INRConvert|31289|c}} (2025)
| num_employees = 27,764 (March 2024)<ref>{{cite web |title=Annual Report 2023-24 |url=https://www.cipla.com/sites/default/files/Annual-Report-2023-24-%28Double%20page%29.pdf |access-date=24 May 2025 |archive-date=5 October 2024 |archive-url=https://web.archive.org/web/20241005175111/https://www.cipla.com/sites/default/files/Annual-Report-2023-24-%28Double%20page%29.pdf |url-status=live }}</ref>
| parent =
| subsid = Invagen Pharmaceuticals
| homepage = [http://www.cipla.com www.cipla.com]
| foundation = {{Start date and age|1935||p=y}}
| location = [[Mumbai]], [[Maharashtra]], India
| footnotes = Financials {{as of|2025|03|31|lc=y|df=yes}}.<ref>{{cite web |title=Q4 & FY25 results |url=https://www.cipla.com/sites/default/files/Cipla_Q4FY25%20Press%20Release_3.pdf |publisher=Cipla |access-date=24 May 2025 |archive-date=14 May 2025 |archive-url=https://web.archive.org/web/20250514161520/https://www.cipla.com/sites/default/files/Cipla_Q4FY25%20Press%20Release_3.pdf |url-status=live }}</ref><ref>{{cite web |title=Audited Financial Results (Standalone and Consolidated) for year ended 31st March 2025 |url=https://www.cipla.com/sites/default/files/signed-Financial-Results-13052025-signed.pdf |publisher=Cipla |access-date=24 May 2025}}</ref>
}}
'''Cipla Limited''' is an Indian [[Multinational corporation|multinational]] [[pharmaceutical]] company headquartered in [[Mumbai]]. Cipla primarily focuses on developing medication to treat [[respiratory disease]], [[cardiovascular disease]], [[arthritis]], [[diabetes]], [[Depression (mood)|depression]], [[Pediatrics|paediatric]] and various other medical conditions. Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer in [[India]].<ref>{{cite news |title=Cipla betting big on digitisation and emerging segments |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cipla-betting-big-on-digitisation-and-emerging-segments/articleshow/93406373.cms |access-date=6 December 2022 |work=The Economic Times}}</ref><ref>{{cite news |title=Cipla betting big on digitisation and emerging segments |url=https://www.financialexpress.com/healthcare/cipla-betting-big-on-digitisation-and-emerging-segments/2620470/ |access-date=6 December 2022 |work=Financial Express |language=en}}</ref>

==History ==
After meeting [[Mahatma Gandhi]] in the early 1920s, [[Khwaja Abdul Hamied]] decided to contribute to the [[Swadeshi movement]] by pursuing a doctorate in chemistry. In 1935, Hamied founded Cipla as the Chemical, Industrial & Pharmaceutical Laboratories in [[Mumbai]].<ref name=History>{{cite web |url=http://www.cipla.com/Home/About-Us/History.aspx |title=About us - History |publisher=Cipla Limited |access-date=3 November 2014 |archive-url=https://web.archive.org/web/20151027060707/http://www.cipla.com/Home/About-Us/History.aspx |archive-date=27 October 2015 |url-status=dead }}</ref><ref name=ETHistory>{{cite web |url=http://economictimes.indiatimes.com/cipla-ltd/infocompanyhistory/companyid-13917.cms |title=Company History - Cipla Ltd. |publisher=Economic Times |access-date=3 November 2013 |archive-date=15 November 2013 |archive-url=https://web.archive.org/web/20131115195132/http://economictimes.indiatimes.com/cipla-ltd/infocompanyhistory/companyid-13917.cms |url-status=live }}</ref> During [[World War II]], the company became the largest supplier of [[quinine]] and [[Vitamin B12]] for [[Allies of World War II|Allied soldiers]].<ref name=":2">{{Cite book |last=Eban |first=Katherine |title=Bottle of Lies |date=2019 |publisher=[[HarperCollins]] |isbn=9780062338785 |pages=69-73}}</ref> The company name shortened to its current form in July 1984.<ref name=ETHistory/> Upon Hamied's death in 1972, his son [[Yusuf Hamied]], a Cambridge-educated chemist, took over the company.<ref name=":2" />

In 1995, Cipla launched [[Deferiprone]], the world's first oral iron chelator.<ref name="History" /> In 1999, Cipla joined the [[Indian Pharmaceutical Alliance]] as a founding member in an effort to promote the development of generic drugs in India.<ref name=":0">{{Cite news |last=Dec 22 |first=PTI |date=2022-12-22 |title=Indian pharma sector set for 'volume to value leadership' journey in 2023 |work=The Economic Times |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/indian-pharma-sector-set-for-volume-to-value-leadership-journey-in-2023/articleshow/96407749.cms |access-date=2023-08-05 |issn=0013-0389 |archive-date=5 August 2023 |archive-url=https://web.archive.org/web/20230805170626/https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/indian-pharma-sector-set-for-volume-to-value-leadership-journey-in-2023/articleshow/96407749.cms |url-status=live }}</ref><ref>{{Cite web |title=Introducing IPA- Indian Pharmaceutical Alliance |url=https://www.ipa-india.org/about-ipa/introduction/ |access-date=2023-08-05 |website=IPA, Indian Pharmaceutical Alliance |archive-date=9 April 2024 |archive-url=https://web.archive.org/web/20240409041116/https://www.ipa-india.org/about-ipa/introduction/ |url-status=live }}</ref> During the [[HIV/AIDS|AIDS]] epidemic in the early 2000s, Hamied reverse-engineered a three-drug [[antiretroviral]] medication that was sold for about $12,000 per year to create a cheaper version that sold for $304 per year.<ref name=":1">{{Cite news |date=2023-08-05 |title=Epic saga of Cipla: How a swadeshi Robin Hood took on Big Pharma of the West |work=The Economic Times |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/epic-saga-of-cipla-how-a-swadeshi-robin-hood-took-on-big-pharma-of-the-west/articleshow/102440967.cms?from=mdr |access-date=2023-08-05 |issn=0013-0389}}</ref> This drug was sold to African charities and governments. It is estimated that "at one time, as much as 40 percent of the AIDS patients in poor countries took Cipla drugs".<ref name=":1" />

During the [[avian flu pandemic]] in 2006, Cipla was able to reverse-engineer the drug Tamiflu and sell it for significantly lower prices.<ref name=":0" /> In 2013, Cipla acquired the [[South Africa]]n company Cipla-Medpro. Its name was changed to Cipla Medpro South Africa Limited and was kept as a subsidiary.<ref name="VC">{{cite news|last1=Jawani|first1=Lohit|title=Cipla completes acquisition of South Africa's Cipla Medpro|url=http://www.vccircle.com/news/pharmaceuticals/2013/07/16/cipla-completes-acquisition-south-africa%E2%80%99s-cipla-medpro|work=VC Circle|date=16 July 2013|access-date=8 September 2016|archive-url=https://web.archive.org/web/20160315164809/http://www.vccircle.com/news/pharmaceuticals/2013/07/16/cipla-completes-acquisition-south-africa%E2%80%99s-cipla-medpro|archive-date=15 March 2016|url-status=dead}}</ref><ref name="Delists">{{cite web|title=Delists from JSE|url=http://www.bdlive.co.za/business/healthcare/2013/07/16/cipla-medpro-delists-from-jse-as-cipla-deal-is-finalised|publisher=Business Day Live|access-date=13 July 2013|date=2013|archive-date=1 August 2013|archive-url=https://web.archive.org/web/20130801130715/http://www.bdlive.co.za/business/healthcare/2013/07/16/cipla-medpro-delists-from-jse-as-cipla-deal-is-finalised|url-status=live}}</ref> At the time of the acquisition, Cipla-Medpro had been a distribution partner for Cipla and was South Africa's third-biggest pharmaceutical company.<ref name="VC" /> The company had been founded in 2002 under the name Enaleni Pharmaceuticals Ltd.<ref>{{cite web|title=Enaleni Pharmaceuticals Limited Prospectus 2005|url=http://globaldocuments.morningstar.com/documentlibrary/document/e00037afcc0c3668.msdoc/original|publisher=Morningstar|access-date=8 September 2016|archive-date=19 September 2016|archive-url=https://web.archive.org/web/20160919174446/http://globaldocuments.morningstar.com/documentlibrary/document/e00037afcc0c3668.msdoc/original|url-status=live}}</ref> In 2005, Enaleni bought all the shares of Cipla-Medpro, which had been a joint venture between Cipla and Medpro Pharmaceuticals, a South African generics company;<ref>{{cite web|last1=Avafia|first1=Tenu|last2=Berger|first2=Jonathan|last3=Hartzenberg|first3=Trudi|title=The ability of select sub-Saharan African countries to utilise TRIPs Flexibilities and Competition Law to ensure a sustainable supply of essential medicines: A study of producing and importing countries|publisher=WHO|url=http://apps.who.int/medicinedocs/documents/s18249en/s18249en.pdf|archive-url=https://web.archive.org/web/20140123042922/http://apps.who.int/medicinedocs/documents/s18249en/s18249en.pdf|url-status=dead|archive-date=23 January 2014|date=2006}}</ref> in 2008, it changed its name to Cipla-Medpro.<ref>{{cite web|last1=Kahn|first1=Tamar|title=South Africa: Enaleni Takes Name of Its Unit Cipla-Medpro|url=http://allafrica.com/stories/200809100609.html|publisher=All Africa|date=10 September 2008}}</ref> In September 2023, it was announced Cipla South Africa had acquired the [[Midrand]]-headquartered healthcare products manufacturer, Actor Pharma.<ref>{{Cite web |last=Priyan |first=Vishnu |date=2023-09-05 |title=Cipla to bolster OTC portfolio with acquisition of Actor Pharma |url=https://www.pharmaceutical-technology.com/news/cipla-acquisition-actor-pharma/ |access-date=2023-09-05 |website=Pharmaceutical Technology |language=en-US |archive-date=5 September 2023 |archive-url=https://web.archive.org/web/20230905140500/https://www.pharmaceutical-technology.com/news/cipla-acquisition-actor-pharma/ |url-status=live }}</ref>

In September 2015, Cipla acquired InvaGen Pharmaceuticals and Exelan Pharmaceuticals, two American pharmaceutical companies, for 555 million dollars.<ref>{{Cite journal |last=JARVIS |first=LISA |title=Mylan Will Buy Most of Matrix |date=2006-09-04 |url=http://dx.doi.org/10.1021/cen-v084n036.p008 |journal=Chemical & Engineering News Archive |volume=84 |issue=36 |pages=8 |doi=10.1021/cen-v084n036.p008 |issn=0009-2347 |url-access=subscription}}</ref> In 2019, Cipla entered [[digital therapeutics]] by partnering with Wellthy Therapeutics in [[India]] and Brandmed in [[South Africa]].<ref>{{Cite web |date=n.d. |title=Cipla's History |url=https://www.cipla.com/about-us/our-history |access-date=2022-05-16 |website=Cipla South Africa |language=en-US |archive-date=26 May 2022 |archive-url=https://web.archive.org/web/20220526182900/https://www.cipla.com/about-us/our-history |url-status=live }}</ref> In April 2024, Cipla acquired Ivia Beaute Pvt Ltd's cosmetics and personal care distribution and marketing business for ₹130 crore.<ref>{{Cite news|url=https://www.business-standard.com/companies/news/cipla-to-acquire-ivia-beaute-s-cosmetics-personal-care-biz-for-rs-130-cr-124041600197_1.html|title=Cipla to acquire Ivia Beaute's cosmetics, personal care biz for Rs 130 cr|newspaper=Business Standard India|date=16 April 2024|agency=Press Trust of India|archive-date=21 April 2024|access-date=21 April 2024|archive-url=https://web.archive.org/web/20240421070218/https://www.business-standard.com/companies/news/cipla-to-acquire-ivia-beaute-s-cosmetics-personal-care-biz-for-rs-130-cr-124041600197_1.html|url-status=live}}</ref>

==Products and services==
Cipla sells [[active pharmaceutical ingredients]] to other manufacturers as well as pharmaceutical and personal care products,<ref name=BW>{{cite web |url=http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=CIPLA:IN |archive-url=https://archive.today/20131106234625/http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=CIPLA:IN |url-status=dead |archive-date=6 November 2013 |title=cipla ltd (CIPLA:Natl India) |publisher=Business Week |access-date=7 November 2013 }}</ref> including the anti-depressant [[escitalopram oxalate]], [[lamivudine]], and [[fluticasone propionate]].<ref>{{cite web |url=https://www.cipla.com/sites/default/files/Annual-Report-FY-2022-23.pdf |title=Annual Report FY 2022-23 |publisher=Cipla |date=15 July 2014 |access-date=October 11, 2023 |archive-url=https://web.archive.org/web/20231011194716/https://www.cipla.com/sites/default/files/Annual-Report-FY-2022-23.pdf |archive-date=2023-10-11 |url-status=live |website=Cipla.com}}</ref> Cipla is the world's largest manufacturer of [[antiretroviral drugs]].<ref name=BW/><ref>{{cite press release |url=http://www.prnewswire.com/news-releases/aids-healthcare-foundation-campaign-challenges-cipla-over-drug-pricing-in-india-profit-at-what-cost-aids-drugs-for-all-57993227.html |title=AIDS Healthcare Foundation Campaign Challenges Cipla Over Drug Pricing in India |publisher=PR Newswire |date=8 August 2007 |access-date=4 November 2013 |archive-date=29 August 2014 |archive-url=https://web.archive.org/web/20140829220651/http://www.prnewswire.com/news-releases/aids-healthcare-foundation-campaign-challenges-cipla-over-drug-pricing-in-india-profit-at-what-cost-aids-drugs-for-all-57993227.html |url-status=live }}</ref>

In July 2020, the company announced the introduction of [[Gilead Sciences]]' [[Remdesivir]] under the brand name CIPREMI in India after reaching a voluntary licensing agreement with the parent company and [[DCGI]] approval for "restricted emergency use" in [[COVID-19]] treatment of patients in critical condition.<ref>{{cite news |date=21 June 2020 |title=India gives Hetero Labs and Cipla approval to make Gilead's COVID-19 drug |language=en |work=Reuters |url=https://www.reuters.com/article/us-health-coronavirus-india-remdesivir/india-gives-hetero-labs-and-cipla-approval-to-make-gileads-covid-19-drug-idUSKBN23S0EO |archive-date=5 August 2020 |access-date=7 August 2020 |archive-url=https://web.archive.org/web/20200805090151/https://www.reuters.com/article/us-health-coronavirus-india-remdesivir/india-gives-hetero-labs-and-cipla-approval-to-make-gileads-covid-19-drug-idUSKBN23S0EO |url-status=live }}</ref><ref>{{cite news |title=Coronavirus drug: Cipla launches Cipremi's, claims it is the cheapest Remdesivir |url=https://www.financialexpress.com/lifestyle/health/cipla-launches-remdesivir-claims-it-is-inexpensive/2018015/ |work=The Financial Express |date=9 July 2020 |archive-date=15 August 2020 |access-date=7 August 2020 |archive-url=https://web.archive.org/web/20200815173602/https://www.financialexpress.com/lifestyle/health/cipla-launches-remdesivir-claims-it-is-inexpensive/2018015/ |url-status=live }}</ref><ref>{{cite news |title=Coronavirus drug: Cipla ramps up production of antiviral remdesivir amid demand spurt |url=https://www.businesstoday.in/current/corporate/coronavirus-drug-cipla-ramps-up-production-of-covid-19-antiviral-remdesivir/story/409758.html |work=businesstoday.in}}</ref>

==Operations==

Cipla has 34 manufacturing units in 8 locations across India and a presence in over 80 countries.<ref>{{cite web|url=http://www.cipla.com/en/corporate-information/at-a-glance.html|title=Corporate Information: At a Glance|publisher=Cipla|access-date=6 July 2019|archive-url=https://web.archive.org/web/20160912104850/http://www.cipla.com/en/corporate-information/at-a-glance.html|archive-date=12 September 2016|url-status=dead}}</ref><ref>{{cite news |url=http://www.business-standard.com/article/news-cm/cipla-in-the-pink-of-health-113092500515_1.html |title=Cipla in the pink of health |newspaper=Business Standard |date=25 September 2013 |access-date=5 November 2013 |archive-date=2 October 2014 |archive-url=https://web.archive.org/web/20141002195051/http://www.business-standard.com/article/news-cm/cipla-in-the-pink-of-health-113092500515_1.html |url-status=live }}</ref> Exports accounted for 48% {{INRConvert|4948|c|lk=|year=2013}} of its revenue for the 2013–14 fiscal year.<ref name=AR201314>{{cite web |url=http://www.cipla.com/CiplaSite/Media/PDF/2014_08_06_78th_Annual_Report_2013_14_001.pdf |title=Annual Report 2013-14 |publisher=Cipla |date=22 August 2014 |access-date=17 September 2014 |archive-url=https://web.archive.org/web/20150122062022/http://www.cipla.com/CiplaSite/Media/PDF/2014_08_06_78th_Annual_Report_2013_14_001.pdf |archive-date=22 January 2015 |url-status=dead }}</ref> Cipla spent {{INR}}517 crore (5.4% of their revenue) in the 2013–14 fiscal year on R&D activities.<ref name=AR201314/> The primary focus areas for R&D were development of new formulations, drug-delivery systems, and APIs. Cipla also cooperates with other enterprises in areas such as consulting, commissioning, engineering, project appraisal, quality control, know-how transfer, support, and plant supply.{{cn|date=July 2025}}

== Listings and shareholding==

The equity shares of Cipla are listed on the [[Bombay Stock Exchange]],<ref>{{cite web |url=http://www.bseindia.com/stock-share-price/cipla-ltd/cipla/500087/ |title=Cipla Limited |website=BSEindia.com |access-date=2 November 2013 |archive-date=4 November 2013 |archive-url=https://web.archive.org/web/20131104221916/http://www.bseindia.com/stock-share-price/cipla-ltd/cipla/500087/ |url-status=live }}</ref> where it is a constituent of the [[BSE SENSEX]] index,<ref>{{cite web |url=http://www.bseindia.com/indices/IndicesWatch_Weight.aspx?iname=BSE30&index_Code=16 |title=Scripwise Weightages in S&P BSE SENSEX |publisher=BSE India |access-date=2 November 2013 |archive-url=https://web.archive.org/web/20151201094728/http://www.bseindia.com/indices/IndicesWatch_Weight.aspx?iname=BSE30&index_Code=16 |archive-date=1 December 2015 |url-status=dead }}</ref> and the [[National Stock Exchange of India]],<ref>{{cite web |url=http://www.nseindia.com/live_market/dynaContent/live_watch/get_quote/GetQuote.jsp?symbol=CIPLA |title=NTPC Limited |publisher=NSE India |access-date=2 November 2013 |archive-date=4 March 2016 |archive-url=https://web.archive.org/web/20160304040205/http://www.nseindia.com/live_market/dynaContent/live_watch/get_quote/GetQuote.jsp?symbol=CIPLA |url-status=live }}</ref> where it is a constituent of the [[CNX Nifty]].<ref>{{cite web |url=http://www.nseindia.com/content/indices/ind_niftylist.csv |title=Download List of CNX Nifty stocks (.csv) |publisher=NSE India |access-date=2 November 2013 |archive-date=13 October 2013 |archive-url=https://web.archive.org/web/20131013143407/http://www.nseindia.com/content/indices/ind_niftylist.csv |url-status=live }}</ref> Its [[Global depository receipt|Global Depository Receipts]] (GDRs) are listed on the [[Luxembourg Stock Exchange]].<ref name=AR201314/>

As of December 31, 2022, the promoter group, Y. K. Hamied and his family, held around 33.61% equity shares in Cipla. Individual shareholders hold approximately 14.72% of its shares. [[SBI Mutual Fund]], [[Life Insurance Corporation of India|LIC]] etc. are the largest non-promoter shareholders in the Company.<ref>{{Cite web |title=StockEdge |url=https://web.stockedge.com/share/cipla/5128?section=shareholders |access-date=2023-01-25 |website=web.stockedge.com |archive-date=25 January 2023 |archive-url=https://web.archive.org/web/20230125133547/https://web.stockedge.com/share/cipla/5128?section=shareholders |url-status=live }}</ref> In January 2024, Samina Hamied resigned from her position as the Executive Vice Chairperson of Cipla. She continued to serve the company as a non-executive director subject to rotational retirement.{{cn|date=July 2025}}

{| class="wikitable"
|-
! Shareholders (as on 31-December-2022) !! Shareholding<ref>{{Cite web |title=Latest CIPLA Shareholding Pattern |url=https://www.equitymaster.com/stock-research/shareholding-pattern/CIPL/CIPLA-Shareholding-Pattern |access-date=2023-01-25 |website=Equitymaster |archive-date=25 January 2023 |archive-url=https://web.archive.org/web/20230125133551/https://www.equitymaster.com/stock-research/shareholding-pattern/CIPL/CIPLA-Shareholding-Pattern |url-status=live }}</ref>
|-
| Promoter Group|| 33.61%
|-
| Mutual funds|| 14.09%
|-
|Financial Institution/Banks/Insurance
|4.96%
|-
| Foreign Institutional Investors (FII)|| 28.39%
|-
|Corporate Bodies
|0.53%
|-
| Individuals|| 14.72%
|-
|NRIs/OCBs
|0.88%
|-
|ADRs/GDRs
|NIL
|-
| Others|| 2.82%
|-

| '''Total'''||'''100.00%'''
|}

==Awards and recognitions==
* In 1980, Cipla won Chemexcil Award for Excellence for exports.<ref name="IIHistory">{{cite web |title=Company Profile - Cipla Limited |url=http://www.indiainfoline.com/Markets/Company/Background/Company-Profile/Cipla-Ltd/500087 |access-date=3 November 2013 |website=IndiaInfoline.com |archive-date=5 November 2013 |archive-url=https://web.archive.org/web/20131105133022/http://www.indiainfoline.com/Markets/Company/Background/Company-Profile/Cipla-Ltd/500087 |url-status=live }}</ref>
* In 2006, Cipla won Dun & Bradstreet American Express Corporate Awards.<ref>{{cite web |date=10 September 2006 |title=Pharmaceutical sector award |url=http://www.dnb.co.in/top500/photogal5.html |url-status=dead |archive-url=https://archive.today/20131104104713/http://www.dnb.co.in/top500/photogal5.html |archive-date=4 November 2013 |access-date=3 November 2013 |publisher=Dun & Bradstreet}}</ref>
* In 2007, [[Forbes Asia|Forbes]] included Cipla in the 200 'Best under a billion' list of best small Asian companies.<ref>{{cite news |date=17 November 2005 |title=Asian Paints, Cipla in Forbes list |newspaper=Economic Times |url=http://articles.economictimes.indiatimes.com/2005-11-17/news/27509362_1_forbes-list-asia-pacific-list-asian-paints |archive-url=https://web.archive.org/web/20131104193134/http://articles.economictimes.indiatimes.com/2005-11-17/news/27509362_1_forbes-list-asia-pacific-list-asian-paints |url-status=dead |archive-date=4 November 2013 |access-date=3 November 2013}}</ref>
* In 2012, Cipla received the Thomson Reuters India Innovation Award.<ref>{{Cite web |url=http://pharmabiz.com/NewsDetails.aspx?aid=72283&sid=1 |title=DBT, Cipla get Thomson Reuters India innovation awards |access-date=24 November 2012 |archive-date=22 July 2013 |archive-url=https://web.archive.org/web/20130722095704/http://pharmabiz.com/NewsDetails.aspx?aid=72283&sid=1 |url-status=dead }}</ref>
* In 2015, Cipla stood third in the India's Most Reputed Brands (Pharmaceutical) list,<ref>"[https://economictimes.indiatimes.com/lupinsun-pharma-and-cipla-amongst-tops-most-reputed-pharma-brand-list/articleshow/53742154.cms Lupin, Sun Pharma and Cipla amongst tops most reputed pharma brand list]". ''The Economic Times''. timesofindia.com. 17 August 2016. Retrieved 6 July 2019.</ref> in a study conducted by BlueBytes,<ref>{{cite web |url=http://www.bluebytes.info/ |title=Home |website=bluebytes.info |access-date=7 August 2022 |archive-date=1 August 2018 |archive-url=https://web.archive.org/web/20180801073109/http://www.bluebytes.info/ |url-status=live }}</ref> a Media Analytics firm in association with TRA Research,<ref>{{cite web |url=http://www.trustadvisory.info/ |title=Home |website=trustadvisory.info |access-date=7 August 2022 |archive-date=2 November 2017 |archive-url=https://web.archive.org/web/20171102143617/http://www.trustadvisory.info/ |url-status=live }}</ref> a brand insights organization (both part of the Comniscient Group).

==Criticism==

===Emergency contraception===
In August 2007, Cipla launched an [[emergency contraception]] drug "i-pill" sold [[over the counter]],.<ref>{{cite news |url=http://www.hindustantimes.com/business-news/cipla-rises-on-morning-after-pill/article1-251319.aspx |archive-url=https://web.archive.org/web/20150205102533/http://www.hindustantimes.com/business-news/cipla-rises-on-morning-after-pill/article1-251319.aspx |url-status=dead |archive-date=5 February 2015 |title=Cipla rises on morning-after pill |newspaper=Hindustan Times |date=5 October 2007 |access-date=3 November 2013}}</ref> The drug sparked controversy as it was available without prescription and contained a large amount of API per dosage.<ref>{{cite news |url=http://healthcare.financialexpress.com/200710/market09.shtml |title=Cipla Launches i-pill |newspaper=Financial Express |access-date=3 November 2013 |archive-date=4 November 2013 |archive-url=https://web.archive.org/web/20131104084353/http://healthcare.financialexpress.com/200710/market09.shtml |url-status=live }}</ref><ref>{{cite news |url=http://www.financialexpress.com/news/-ipill-by-cipla-draws-criticism-from-experts/232556 |title='i-pill' by Cipla draws criticism from experts |newspaper=Financial Express |date=27 October 2007 |access-date=3 November 2013 |archive-date=4 November 2013 |archive-url=https://web.archive.org/web/20131104081841/http://www.financialexpress.com/news/-ipill-by-cipla-draws-criticism-from-experts/232556 |url-status=live }}</ref>

===Generic drugs===
In the late 1960s, Cipla began manufacturing a new, patented drug, [[propranolol]], without the permission of the drug's patent holder, [[Imperial Chemical Industries]]; a protest was filed with the Indian government. The CEO of Cipla pressured the [[First Indira Gandhi ministry|government of Indira Gandhi]] to change India's [[patent laws]] to eliminate patents that directly covered drugs, and instead to allow only patents that covered [[chemical synthesis|methods to make drugs]]<ref name=Wired>{{cite news |url=https://www.wired.com/wired/archive/14.12/indiadrug.html |title=The Treasure of Mumbai |newspaper=Wired Magazine |date=December 2006 |access-date=4 November 2013}}</ref> so that Cipla could produce low-priced generic drugs. Since then, Cipla has also produced a low-cost drug to treat HIV, and expanded operations into several developing countries.<ref name=nationalherald>{{cite news |url=https://www.nationalheraldindia.com/india/heart-warming-story-of-the-hamieds-who-set-up-cipla-and-have-been-saving-lives |title= Heart-warming story of the Hamieds, who set up CIPLA and have been saving lives |newspaper=National Herald |date=April 2020 |access-date=12 April 2020}}</ref> The changes made led to criticism of both India's patent laws and Cipla.<ref>{{cite web |url=http://biohealthinvestor.com/2007/01/indian-generic-drug-maker-targets-sad-americans.html |title=Indian Generic Drug Maker Targets Sad Americans |website=biohealthinvestor.com |date=3 January 2007 |access-date=4 November 2013 |archive-date=22 August 2012 |archive-url=https://web.archive.org/web/20120822022509/http://biohealthinvestor.com/2007/01/indian-generic-drug-maker-targets-sad-americans.html |url-status=live }}</ref> India reinstated patents on drugs in 2005.<ref name=Wired/>

==See also==

* [[Pharmaceutical industry in India]]
* [[Generic drug]]
* [[List of pharmaceutical companies]]

==References==
{{reflist}}

==External links==
* {{Official website|http://www.cipla.com}}
{{Portal bar|Companies|India}}
{{Nifty 200 companies}}
{{CNX Nifty companies}}
{{Authority control}}

[[Category:Biotechnology companies of India]]
[[Category:Pharmaceutical companies of India]]
[[Category:Pharmaceutical companies established in 1935]]
[[Category:NIFTY 50]]
[[Category:Pharmaceutical companies]]
[[Category:Indian brands]]
[[Category:Indian companies established in 1935]]
[[Category:Companies listed on the National Stock Exchange of India]]
[[Category:Companies listed on the Bombay Stock Exchange]]
[[Category:Multinational companies headquartered in India]]

Cipla - Revision history

MarcyEdmond490 at 09:02, 18 February 2026